Does Medicaid cover GLP-1? The 10 states that still pay for weight loss (November 2026)

Does Medicaid cover GLP-1 drugs? Every state program covers them for type 2 diabetes, but only 10 pay for weight loss as of November 5, 2026. Those 10 are Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Virginia and Wisconsin. Michigan and Virginia only approve weight-loss use at a BMI near 40.

In the other 41 programs, the answer turns on the diagnosis rather than the weight. Wegovy has FDA approvals for heart risk and fatty liver disease, and Zepbound for sleep apnea, so most states still cover them with prior authorization. We call that the indication-first coverage check, and it’s the most useful step for anyone outside the 10.

Key takeaways

As of November 5, 2026, 10 programs pay for weight loss: Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Virginia and Wisconsin.

Seven programs stopped in 2026: California, New Hampshire, Pennsylvania and South Carolina on January 1, then Utah, Massachusetts and Rhode Island mid-year.

Run the indication-first coverage check first. Heart risk, fatty liver disease and sleep apnea can open GLP-1 coverage where weight loss is excluded.

CMS’s BALANCE model lets state Medicaid programs join through January 1, 2027, but no participating state has launched coverage yet.

Our analysis: programs that have covered weight loss filled a median 230 GLP-1 prescriptions per 1,000 adult enrollees in 2024, against 158 elsewhere.

Does Medicaid cover GLP-1 for weight loss?

Only in 10 state programs. Federal law lets each state exclude weight-loss drugs, but not GLP-1s prescribed for other medically accepted uses like diabetes or sleep apnea.

The exclusion comes from Section 1927(d)(2) of the Social Security Act, which lists drugs used for weight loss as ones a state may restrict. So the question of whether Medicaid covers GLP-1 for obesity has 51 answers, one per program. Every program that says yes still requires prior authorization.

Counts online disagree because the list moved all year. KFF counted 13 programs in January 2026. Utah, Massachusetts and Rhode Island stopped after that, which leaves 10. Any page still naming 13 is reading a January snapshot of Medicaid GLP-1 coverage in 2026.

Two rules hold everywhere. A GLP-1 covered by Medicaid for diabetes is covered in all 51 programs. Ozempic or Mounjaro written for weight loss alone is off-label, so no program has to pay for it.

Which state Medicaid programs cover GLP-1 for weight loss?

As of November 5, 2026, Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Virginia and Wisconsin cover GLP-1s for weight loss. Michigan and Virginia restrict it to severe obesity.

We checked each program against its own preferred drug list (PDL), bulletin or prior authorization form, linked in the last column. For the 41 programs that don’t pay for weight loss, the drug column shows what they still cover instead.

Verified November 5, 2026. An asterisk marks a program whose agency site failed to load that day (Alabama, Mississippi) or whose PDL could not be opened (Idaho). Those statuses rest on secondary trackers and no reported change.

A few rows answer the most searched state questions directly. Does Medicaid cover GLP-1 in Colorado? Only for heart disease, sleep apnea or MASH, since the PDL says weight-loss-only requests will not be approved. Does Medicaid cover GLP-1 in Florida? Only for diabetes, and even that needs an A1c of 6.5% and a metformin trial.

Does Medicaid cover GLP-1 in Michigan? Yes, but only at a BMI of 40 after every other option fails. And does Missouri Medicaid cover GLP-1 for weight loss? Yes for Zepbound and Foundayo, while Missouri limits Wegovy to heart risk and MASH.

Managed care plans mostly follow the state list. New Hampshire’s and Pennsylvania’s notices name both fee-for-service and managed care plans. North Carolina bars its plans from adding extra hurdles to the obesity drug class.

What changed in 2026

Seven programs stopped paying for GLP-1 weight loss in 2026, one reinstated coverage and one widened it. Every stop notice we read cites budgets.

• January 1: California, New Hampshire, Pennsylvania and South Carolina ended weight-loss coverage.
• June 30: Utah’s fee-for-service weight-loss coverage ended when its pilot funding ran out.
• July 3: Massachusetts ended obesity-only coverage across every MassHealth plan type.
• October 1: Rhode Island stopped covering Foundayo, Saxenda, Wegovy and Zepbound for weight loss alone, under its fiscal 2027 budget.
• Reinstated: North Carolina cut coverage on October 1, 2025, then restored it on December 12, 2025.
• Widened: Kansas moved Foundayo onto its standard pathway on November 1, 2026, with 28-week approvals at a BMI of 30.
• Watch list: Louisiana’s Act 898 requires coverage only once funded. Maryland’s SB 496 allows coverage from 2027, and Indiana has new PA criteria for January 1, 2027.

Does Medicaid cover GLP-1 in PA now? Not for weight loss. Pennsylvania’s Medical Assistance Bulletin ended obesity coverage on January 1, 2026, and voided every prior authorization on December 31, 2025. Saxenda lost coverage for every use.

The bulletin covers fee-for-service and managed care alike. So does Keystone First cover Wegovy for weight loss? No, though it still can for heart risk or MASH with a new prior authorization. Under-21s may still qualify through EPSDT, the federal children’s benefit, according to the Pennsylvania Health Law Project rather than the bulletin.

Our analysis: the 2026 cuts fell on lower-obesity states

We compared each group’s 2024 adult obesity rate from CDC survey data. The seven programs that cut coverage have a median rate of 31.1%. The nine that kept it have 36.1%, because Tennessee has no 2024 figure.

A permutation test puts the odds of a five-point split arising by chance at p = 0.02, or about one in 50. The groups are small, and the data can’t show why any state cut. For the all-payer picture, see our breakdown of GLP-1 use by state.

Covered states fill more Medicaid GLP-1 prescriptions

Programs that have covered weight loss at some point filled a median 230 GLP-1 prescriptions per 1,000 adult enrollees in 2024. The 34 that never did filled 158. That’s 1.46 times as many (p = 0.0045), from our analysis of CMS State Drug Utilization Data and CMS enrollment counts.

The count can’t separate diabetes from weight-loss prescriptions, so high rates in uncovered states are mostly diabetes prescribing. Six never-covered programs still fill above the covered median, as the plot below shows.

State rankings by fill rate are published elsewhere. Our addition is the split by coverage history, which is the comparison in the plot above.

Covered for something else: the indication-first coverage check

The indication-first coverage check asks which FDA-approved condition the patient has before asking whether the state covers weight loss. Diabetes, heart risk, fatty liver disease and sleep apnea all open GLP-1 coverage in non-covering states.

States must cover a drug for its medically accepted uses even when they exclude weight loss. That’s why 41 programs that refuse Wegovy for obesity still list it for other conditions.

Worked example: BMI 32 with sleep apnea in Pennsylvania

Take an adult on Pennsylvania Medicaid with a BMI of 32 and diagnosed obstructive sleep apnea. Weight-loss coverage ended on January 1, 2026, so a Wegovy request for obesity is denied.

Run the indication-first coverage check instead. Sleep apnea with obesity is still covered with prior authorization, so the prescriber requests Zepbound for sleep apnea, attaching the sleep study.

The same patient in Ohio would hit a wall, because Ohio’s list has no Zepbound pathway for sleep apnea. Florida’s criteria list no heart, sleep apnea or liver pathway at all. Where a list shows none, ask the state pharmacy help desk about its exception process, like Washington’s exception-to-rule route.

Does Medicaid cover Zepbound?

Yes, with prior authorization, for sleep apnea in most programs and for weight loss in the 10 that cover it. Zepbound is preferred in Missouri, North Carolina, Tennessee and Wisconsin.

Does Medicaid cover tirzepatide under its diabetes brand? Mounjaro is a diabetes GLP-1, so it’s covered for type 2 diabetes. Zepbound is the same molecule with weight and sleep apnea approvals, and states treat it under those rules.

Two details trip people up. North Carolina prefers the Zepbound pen and removed the vial on September 4, 2026. Massachusetts covers Zepbound for sleep apnea only after a Wegovy trial.

Does Medicaid cover Foundayo? Foundayo is orforglipron, Eli Lilly’s daily GLP-1 pill, and seven covering programs list it. Missouri, North Carolina and Wisconsin prefer it.

Does Medicaid cover Ozempic for weight loss?

No. Ozempic is approved for type 2 diabetes, so prescribing it for weight loss is off-label and no Medicaid program has to pay. Covering states list Wegovy instead.

Wegovy is the same molecule, semaglutide, at a different dose with its own weight-management approval. Our GLP-1 medication list pairs each diabetes brand with its weight-loss counterpart.

Does Medicaid cover Ozempic for prediabetes? Generally not. Prediabetes on its own isn’t a type 2 diabetes diagnosis, and Florida’s criteria require an A1c of 6.5% or higher. In Missouri, prediabetes counts as a comorbidity for weight-loss coverage at a BMI of 27.

What Medicaid prior authorization asks for

All 10 covering programs require prior authorization, and their forms ask for much the same evidence. The common criteria follow, with the outliers named.

• BMI: 30 or more, or 27 or more with a weight-related condition. Michigan needs 40, and Virginia over 40, or over 37 with dyslipidemia, hypertension or type 2 diabetes.
• Earlier treatment: Virginia needs a failed non-GLP-1 weight-loss drug first. Michigan wants every other intervention tried, including five preferred non-GLP-1 drug types.
• Lifestyle program: Tennessee, Virginia, Wisconsin and Minnesota want a documented diet and activity program.
• Baseline weight: North Carolina wants a BMI recorded within 45 days of the request, and Kansas requires a baseline weight.
• Approval length: Delaware, Minnesota, Michigan and Virginia approve 6 months at a time, Kansas 28 weeks, and Missouri 4 weeks through dose titration.
• Renewal targets: Delaware, Minnesota, North Carolina and Virginia want at least 5% weight loss. Kansas wants 5% at 12 weeks and 10% at 28 weeks, and Tennessee more than 10% after a year.
• One drug at a time: Mississippi and Wisconsin won’t approve two GLP-1s together.
• Teens: Kansas, Missouri, Minnesota and North Carolina cover ages 12 to 17 using BMI percentiles or weight thresholds. Wisconsin covers Wegovy only for ages 12 to 17.

If a request is denied, the denial letter states the appeal route and the deadline. Act on that letter rather than a general rule, because the deadlines differ by state and by plan.

Will Medicaid cover GLP-1s in 2027?

Only where a state opts in. CMS’s BALANCE model lets Medicaid programs join through January 1, 2027, but no state has launched coverage through it yet.

The BALANCE model page, updated September 29, 2026, says applications were due July 31, 2026, and names no participants. Indiana announced on July 30, 2026 that it will join, with no start date. Maryland’s drug affordability board recommended joining, and Delaware’s state plan now allows it.

The state net price is confidential, according to KFF. CMS also dropped the Medicare Part D side for 2027 after too few plans signed up.

For GLP-1 insurance coverage in 2026 outside Medicaid, the Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027 at $50 a month. The Bridge is for Medicare enrollees only. Our GLP-1 statistics roundup tracks spending across payers.

How weight-loss practices handle Medicaid GLP-1 requests

In the weight-loss practices we work with, the Medicaid question usually reaches the front desk before it reaches the prescriber. A fixed order keeps the answer consistent.

1. Run the indication-first coverage check at intake. Ask about diabetes, heart disease, fatty liver disease and sleep apnea before discussing weight-loss coverage.
2. Confirm the state’s current status. Check the patient’s row in the state table and the PDL date, since seven programs stopped paying this year.
3. Capture the evidence at the first visit. Record BMI, comorbidities and lifestyle program participation the way the PA form asks, using a weight loss intake form.
4. Submit the prior authorization and diary the renewal. Many approvals run 6 months or 28 weeks, so book the weigh-in before it lapses.
5. Follow the denial letter. Its appeal deadline is the one that counts.
6. Give the self-pay route if coverage fails. NovoCare lists the Wegovy pen at $199 a month for new patients’ first two months, then $349. Lilly lists the Zepbound KwikPen from $299 to $449, depending on dose.

Manufacturer copay cards exclude Medicaid, so the self-pay prices above are the realistic fallback. Keeping these steps in one EMR for weight loss saves the front desk from rebuilding each request.

Keeping Medicaid GLP-1 patients on track with Pabau

A Medicaid GLP-1 request is only as strong as the evidence attached to it, and that evidence is scattered across intake, notes and letters. Pabau, the all-in-one practice management system we build, keeps it in one place for weight-loss practices.

Intake forms capture BMI, comorbidities and lifestyle program details before the first visit. The details a PA form asks for are then already on file. Approval letters and sleep study results sit in Client records next to the treatment notes, so nobody hunts for them at renewal.

Pabau also handles insurance billing. In the US, eligibility verification runs through Claim.MD before the visit. Prior authorizations are stored as cases that show how many approved sessions have been used.

Follow-up appointments with automated reminders keep the reauthorization weigh-in on the calendar. See how it fits a full weight loss clinic software setup.

Keep GLP-1 approvals and renewals on track

Pabau keeps intake data, approval letters and renewal weigh-ins in each patient’s record, so your team submits complete requests and renews them on time.

Book a demo

Conclusion

For most Medicaid patients, the weight-loss answer is no, and that will hold until a state funds BALANCE or reverses a cut. The coverage question then becomes a diagnosis question, and that one often has a yes.

Practices that ask about heart disease, liver disease and sleep apnea first will get approvals that weight-first practices never request. The trade-off is documentation, because every route runs through prior authorization and a renewal date. Book a demo to see how Pabau keeps GLP-1 approvals, renewals and patient records together for weight-loss practices.

Continue your research

Screening patients before a semaglutide start? Ozempic questionnaire gives you a ready intake form for GLP-1 candidates.

Starting patients on tirzepatide? Tirzepatide informed consent template covers the consent wording for Mounjaro treatment.

Pairing medication with nutrition? GLP-1 diet plan sets out meals that suit patients on GLP-1 therapy.

Planning care for patients with obesity? Obesity nursing care plan structures goals, interventions and follow-up.

Weighing the economics of a GLP-1 program? How weight loss clinics make money breaks down revenue models for weight-loss practices.

Frequently asked questions